

# BMJ Open Disease history and risk of comorbidity in women's life course: a comprehensive analysis of the Japan Nurses' Health Study baseline survey

Kazue Nagai,<sup>1</sup> Kunihiro Hayashi,<sup>1</sup> Toshiyuki Yasui,<sup>2</sup> Kota Katanoda,<sup>3</sup> Hiroyasu Iso,<sup>4</sup> Yutaka Kiyohara,<sup>5</sup> Akihiko Wakatsuki,<sup>6</sup> Toshiro Kubota,<sup>7</sup> Hideki Mizunuma<sup>8</sup>

**To cite:** Nagai K, Hayashi K, Yasui T, *et al*. Disease history and risk of comorbidity in women's life course: a comprehensive analysis of the Japan Nurses' Health Study baseline survey. *BMJ Open* 2015;5:e006360. doi:10.1136/bmjopen-2014-006360

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2014-006360>).

Received 14 August 2014  
Revised 26 December 2014  
Accepted 1 February 2015



CrossMark

For numbered affiliations see end of article.

## Correspondence to

Professor Kunihiro Hayashi;  
khayashi@gunma-u.ac.jp

## ABSTRACT

**Objective:** To classify diseases based on age at peak incidence to identify risk factors for later disease in women's life course.

**Design:** A cross-sectional baseline survey of participants in the Japan Nurses' Health Study.

**Setting:** A nationwide prospective cohort study on the health of Japanese nurses. The baseline survey was conducted between 2001 and 2007 (n=49 927).

**Main outcome measures:** Age at peak incidence for 20 diseases from a survey of Japanese women was estimated using the Kaplan-Meier method with the Kernel smoothing technique. The incidence rate and peak incidence for diseases whose peak incidence occurred before the age of 45 years or before the perimenopausal period were selected as early-onset diseases. The OR and 95% CI were estimated to examine the risk of comorbidity between early-onset and other diseases.

**Results:** Four early-onset diseases (endometriosis, anaemia, migraine headache and uterine myoma) were significantly correlated with one another. Late-onset diseases significantly associated (OR>2) with early-onset diseases included comorbid endometriosis with ovarian cancer (3.65 (2.16 to 6.19)), endometrial cancer (2.40 (1.14 to 5.04)) and cerebral infarction (2.10 (1.15 to 3.85)); comorbid anaemia with gastric cancer (3.69 (2.68 to 5.08)); comorbid migraine with transient ischaemic attack (3.06 (2.29 to 4.09)), osteoporosis (2.11 (1.71 to 2.62)), cerebral infarction (2.04 (1.26 to 3.30)) and angina pectoris (2.00 (1.49 to 2.67)); and comorbid uterine myoma with colorectal cancer (2.31 (1.48 to 3.61)).

**Conclusions:** While there were significant associations between four early-onset diseases, women with a history of one or more of the early-onset diseases had a higher risk of other diseases later in their life course. Understanding the history of early-onset diseases in women may help reduce the subsequent risk of chronic diseases in later life.

## INTRODUCTION

Women experience various diseases at different life stages that correspond to reproductive

## Strengths and limitations of this study

- This study examined comprehensively the risks of comorbidity between early-onset gynaecological diseases and other subsequent chronic diseases in later life.
- Age at peak incidence for 20 diseases from a large study population was estimated.
- The study population, which was composed entirely of female nurses, is likely to report disease history more accurately than general population.
- Data on disease histories were collected retrospectively, so only living participants were included in the study.
- Women over the age of 60 years were under-represented relative to other age groups in the study.

health-related events such as menarche and menopause.<sup>1</sup> In particular, postmenarchal and premenopausal women may develop oestrogen-dependent diseases such as endometriosis and uterine myoma.<sup>2</sup> While some diseases decline in frequency after menopause, others, such as hyperlipidaemia, occur more frequently, demonstrating that menopause represents a major transition event in a woman's life course.<sup>3-5</sup>

In women's health, it is important to understand how the history of gynaecological diseases that occur during premenopausal ages affects the risk of diseases that occur during perimenopausal or postmenopausal ages, from a life-course epidemiological point of view. A number of previous studies have highlighted the co-occurrence of gynaecological diseases with other disorders, such as the increased risk of ovarian cancer in women with endometriosis,<sup>6</sup> the association between blood oestrogen levels and migraine in women,<sup>7 8</sup> and the link between migraine and cardiovascular risk.<sup>9</sup> However, few epidemiological studies have

comprehensively examined the risks of comorbidity between early-onset gynaecological diseases and other subsequent chronic diseases in later life.

The Japan Nurses' Health Study (JNHS) is a large-scale prospective cohort study investigating the effects of lifestyle, healthcare practices and history of diseases on women's health.<sup>10</sup> In the cross-sectional baseline mail survey of the study, we investigated the prevalence of past diagnosis and age at first diagnosis for various diseases. The study population was designed for female registered nurses, public health nurses and midwives who were at least 25 years of age and resident in Japan at the baseline survey. Nurses were preferred as the study population because they were expected to accurately report medical information such as disease history. The objectives of this study were to classify diseases that occur frequently in women by identifying age at peak incidence and demonstrating their co-occurrence with other diseases based on the JNHS baseline data.

## METHODS

### Survey participants

The study population comprised 49 927 female nurses who participated between 2001 and 2007 in the cross-sectional baseline survey of the JNHS, a nationwide prospective cohort study. The size of the study population was set to detect an increase of 1.5 or more in relative risk in the 10-year follow-up phase of the JNHS. The details of the study plan and the sample size calculation have been presented elsewhere.<sup>5 10</sup> Data were obtained from a self-administered postal questionnaire covering a range of health topics including lifestyle habits, disease history, reproductive health and medication use.<sup>10</sup> We included 48 632 women whose responses to the questions on disease histories were completed. Participants were informed of the study's purpose and procedures before recruitment.

### Medical history questionnaire

Disease history was ascertained using a questionnaire. The baseline survey investigated participants' medical histories and obtained information on previous diagnoses, age at first diagnosis and treatment histories for a range of major medical disorders.

### Diseases analysed and definition of comorbidity

We excluded diseases from the analysis that had a prevalence based on the diagnosis history of less than 0.001. We analysed 20 diseases including hypertension, angina pectoris, subarachnoid haemorrhage, cerebral infarction, transient ischaemic attack (TIA), diabetes mellitus, thyroid disease, hypercholesterolaemia, cholelithiasis, endometriosis, uterine myoma, cervical cancer, endometrial cancer, ovarian cancer, breast cancer, gastric cancer, colorectal cancer, osteoporosis, anaemia and migraine. Comorbidity was defined as the co-occurrence of two diseases based on a participant's disease history at baseline survey regardless of the timing of disease onset.

## Statistical analysis

We estimated the cumulative incidence and 95% CI by the Kaplan-Meier survival analysis (product-limit method). In the survival analyses, we treated incidence at the age of first diagnosis as an event in women with a history of the disease and the observation was censored at the age recorded in the baseline survey in women without a history of the disease.<sup>11</sup> We estimated the age at peak incidence using the Kernel smoothing method (Epanechnikov Kernel) and defined early-onset diseases (diseases occurring frequently before the perimenopausal period) as those having a peak incidence at less than 45 years of age.<sup>12</sup>

To examine the risk of comorbidity between early-onset diseases and other diseases, ORs and 95% CIs were calculated. A statistical analysis was conducted to examine homogeneity by the Breslow-Day test and to estimate a common OR by the Mantel-Haenszel method between the two age groups (<50 years or ≥50 years). The crude ORs were also calculated as part of a sensitivity analysis. Statistical significance was set at the 5% level (two tailed) and no adjustments were made for multiplicity. All analyses were performed using SAS V.9.4 (SAS Institute Inc., Cary, North Carolina, USA).

## RESULTS

### Subject characteristics

Of the 49 927 women who participated in the JNHS baseline survey, 48 632 who responded to the questions of disease histories were included in the analysis. The average age (SD) at the time of the baseline survey was 41.2 (7.9) years. The smoking prevalence in the study population was 17.2% (table 1). In addition, 22.7% of respondents reported consuming alcoholic beverages more than three times per week. Most women, 32 642 (67.1%), were married at the time of the baseline survey and 32 295 (66.4%) were parous. Only 6086 women (12.5%) were postmenopausal. The average reported age at menopause (SD) in the postmenopausal women was 49.1 (4.4) years.

### Incidence of past diagnosis by disease

The cumulative incidences estimated by the Kaplan-Meier method at 30, 40, 50 and 60 years of age are shown in table 2. The high cumulative incidence at 50 years of age, around the mean age at menopause, was 29.0% for anaemia, 18.9% for uterine myoma, 13.0% for hypercholesterolaemia, 10.7% for migraine headache, 9.0% for hypertension, 7.4% for endometriosis and 6.0% for thyroid disease.

On the basis of the age at peak incidence of disease estimated by Kernel smoothing, the early-onset diseases that had a peak of incidence before 45 years of age (before the perimenopausal period) were endometriosis (36 years), anaemia (36 years), migraine headache (44.8 years), uterine myoma (44.8 years) and cervical cancer (44.8 years). Figure 1A shows the Kernel

**Table 1** Characteristics of study population at baseline survey

Characteristics	N	Proportion (%)
Age (year)		
<30	938	1.9
30–34	11 174	23.0
35–39	10 163	20.9
40–44	9656	19.9
45–49	8155	16.8
50–54	5929	12.2
55–59	2217	4.6
60–64	339	0.7
65≤	61	0.1
Smoking status		
Non-smoker	33 918	69.7
Current smoker	8388	17.2
Ex-smoker	5648	11.6
Missing	678	1.4
Alcohol intake		
Non-drinker	14 224	29.2
<3 day/week	20 391	41.9
≥3 day/week	11 024	22.7
Missing	2993	6.2
Marital status		
Unmarried	11 633	23.9
Married	32 642	67.1
Divorced	2850	5.9
Separated/widowed	980	2.0
Missing	527	1.1
Pregnancy		
Never	12 786	26.3
Ever	33 618	69.1
Missing	2228	4.6
Delivery		
Never	14 328	29.5
Ever	32 295	66.4
Missing	2009	4.1
Menopause status		
Premenopause	40 010	82.3
Postmenopause	6086	12.5
Unknown	1947	4.0
Missing	589	1.2

smoothing estimates of incidence for these early-onset diseases. The peak incidence of thyroid disease, breast cancer and cholelithiasis occurred between 45 and 54 years of age, or in the perimenopausal period ([figure 1B](#)). For the other 12 diseases (subarachnoid haemorrhage, TIA, endometrial cancer, diabetes mellitus, gastric cancer, cerebral infarction, ovarian cancer, colorectal cancer, angina pectoris, osteoporosis, hypertension and hypercholesterolaemia), the peak incidence occurred after 55 years of age, or in the postmenopausal period ([table 2](#)).

### Comorbidity among early-onset diseases

The early-onset diseases were endometriosis, anaemia, migraine, uterine myoma and cervical cancer. Four early-onset diseases (endometriosis, anaemia, migraine

headache and uterine myoma) were significantly correlated with one another ([table 3](#)). It is worth noting that the OR (95% CI) for comorbid endometriosis and uterine myoma was 4.47 (4.09 to 4.87).

### Comorbidity of four early-onset diseases and other diseases

The study population was stratified by age at survey into two strata, less than 50 years and 50 years of age or older. Examination for homogeneity of ORs across strata using the Breslow-Day test revealed that the risk of comorbidity was statistically heterogeneous for hypertension and hypercholesterolaemia in women with endometriosis, diabetes mellitus, osteoporosis, hypertension and hypercholesterolaemia in women with anaemia, thyroid disease, diabetes mellitus, angina pectoris, hypertension and hypercholesterolaemia in women with uterine myoma ([table 3](#)). In all of those comorbidities, the OR in the older age stratum was lower than in the younger age stratum. The strength of the association was diminished in the older stratum. The only statistically negative association of anaemia and diabetes mellitus was also heterogeneous between age strata (Breslow-Day test:  $p=0.028$ ), indicating that the negative association was stronger in the older stratum, with the OR changing from 0.86 in <50 years to 0.54 in the ≥50 years of age stratum.

The common ORs (95% CI) greater than 2.00 for comorbid endometriosis were 3.65 (2.16 to 6.19), 2.40 (1.14 to 5.04) and 2.10 (1.15 to 3.85) for ovarian cancer, endometrial cancer and cerebral infarction, respectively. The common OR greater than 2.00 for comorbid anaemia was 3.69 (2.68 to 5.08) for gastric cancer. The common OR for comorbid anaemia and diabetes mellitus was significantly lower, 0.68 (0.56 to 0.84). The common ORs greater than 2.00 for comorbid migraine headache were 3.06 (2.29 to 4.09), 2.11 (1.71 to 2.62), 2.04 (1.26 to 3.30) and 2.00 (1.49 to 2.67) for TIA, osteoporosis, cerebral infarction and angina pectoris, respectively. The common OR greater than 2.00 for comorbid uterine myoma was 2.31 (1.48 to 3.61) for colorectal cancer only ([table 3](#)). The crude ORs without stratification were used in a sensitivity analysis. Similar estimates were obtained (data not shown).

## DISCUSSION

The age at peak incidence of diseases in Japanese women varies in the premenopausal, perimenopausal and postmenopausal periods. The early-onset diseases (those with a peak incidence before 45 years of age) were endometriosis, anaemia, migraine headache, uterine myoma and cervical cancer. The associations found in this comprehensive study between early-onset diseases and other diseases suggest that women with a history of early-onset diseases have a higher risk of other diseases later in their life course. Understanding the history of early-onset diseases in women may help reduce any subsequent risk of chronic diseases in later life.

**Table 2** Incidence peak and cumulative incidence for the K-M estimate

	Incidence peak* (%)	Age at incidence peak (years)	Cumulative incidence (%)							
			30 years	40 years	50 years	60 years				
			K-M estimate	95% CI	K-M estimate	95% CI	K-M estimate	95% CI	K-M estimate	95% CI
Endometriosis	0.25	36.0	2.19	2.07 to 2.33	4.91	4.70 to 5.12	7.36	7.06 to 7.67	7.76	7.41 to 8.12
Anaemia	0.85	36.0	12.4	12.1 to 12.7	19.2	18.8 to 19.5	29.0	28.5 to 29.6	31.8	31.1 to 32.6
Migraine headache	0.32	44.8	4.51	4.32 to 4.70	7.68	7.43 to 7.93	10.7	10.3 to 11.1	12.8	12.2 to 13.5
Uterine myoma	1.11	44.8	1.22	1.12 to 1.32	6.81	6.56 to 7.07	18.9	18.3 to 19.4	22.9	22.1 to 23.7
Cervical cancer	0.04	44.8	0.09	0.06 to 0.12	0.57	0.50 to 0.65	1.11	0.98 to 1.25	1.37	1.13 to 1.65
Thyroid disease	0.26	49.2	1.60	1.49 to 1.71	3.41	3.24 to 3.59	6.00	5.71 to 6.31	9.39	8.64 to 10.2
Breast cancer	0.10	50.0	0.04	0.03 to 0.06	0.33	0.27 to 0.39	1.50	1.33 to 1.70	2.72	2.20 to 3.37
Cholelithiasis	0.23	52.2	0.44	0.38 to 0.50	1.42	1.30 to 1.54	3.26	3.03 to 3.50	6.15	5.42 to 6.96
Subarachnoid haemorrhage	0.03	55.1	0.01	0.01 to 0.03	0.05	0.03 to 0.08	0.17	0.12 to 0.24	0.44	0.27 to 0.74
Transient ischaemic attack	0.07	55.1	0.14	0.11 to 0.18	0.29	0.24 to 0.35	0.66	0.56 to 0.77	1.50	1.10 to 2.04
Endometrial cancer	0.02	55.9	0.00	0.00 to 0.01	0.04	0.03 to 0.07	0.16	0.11 to 0.24	0.51	0.32 to 0.81
Diabetes mellitus	0.38	57.3	0.08	0.06 to 0.11	0.41	0.35 to 0.49	1.92	1.73 to 2.14	6.49	5.57 to 7.55
Gastric cancer	0.05	57.3	0.03	0.02 to 0.05	0.16	0.12 to 0.21	0.52	0.42 to 0.63	0.98	0.67 to 1.43
Cerebral infarction	0.11	58.8	0.02	0.01 to 0.03	0.06	0.04 to 0.10	0.28	0.21 to 0.37	1.36	0.95 to 1.94
Ovarian cancer	0.06	63.9	0.06	0.04 to 0.08	0.13	0.10 to 0.17	0.28	0.21 to 0.36	0.38	0.25 to 0.57
Colorectal cancer	0.14†	≥65‡	0.01	0.00 to 0.02	0.04	0.03 to 0.07	0.34	0.26 to 0.45	0.97	0.70 to 1.34
Angina pectoris	0.56†	≥65‡	0.04	0.03 to 0.06	0.20	0.16 to 0.25	0.99	0.85 to 1.15	3.03	2.46 to 3.74
Osteoporosis	2.23†	≥65‡	0.07	0.05 to 0.09	0.26	0.21 to 0.32	1.18	1.03 to 1.35	6.73	5.73 to 7.89
Hypertension	3.86†	≥65‡	0.36	0.31 to 0.42	1.74	1.61 to 1.88	9.05	8.62 to 9.49	23.4	21.9 to 25.0
Hypercholesterolaemia	4.74†	≥65‡	0.94	0.86 to 1.03	3.27	3.10 to 3.45	13.0	12.5 to 13.5	41.3	39.4 to 43.2


\*Incidence peak was estimated by the Kernel smoothing technique.

†Incidence at 65 years of age.

‡Age at incidence peak was undetermined because age-specific incidence was hockey stick shaped until age 65 years.

K-M, Kaplan-Meier.





**Figure 1** (A) Kernel smoothing estimates of incidence for early-onset diseases with a peak incidence before 45 years of age. (B) Kernel smoothing estimates of incidence for diseases with a peak incidence between 45 and 54 years of age.

In this study, we observed a skewed age distribution because of the smaller sample size of participants aged 50 years or older. We stratified the study population by age at the time of the survey into two strata (<50 years and  $\geq 50$  years of age) and examined the homogeneity of ORs between the age groups. In addition, we estimated the common ORs between the two age groups instead of overall crude ORs to adjust for the skewed age distribution. However, statistical significance in the comorbidity of very late-onset diseases such as osteoporosis was unlikely because of the small sample size in the older age group.

For endometriosis, the estimated age at peak incidence was 36 years of age and the cumulative incidence at 50 years of age was 7.4%; thus, endometriosis could be considered a common gynaecological disorder in relatively young women. Endometriosis is characterised by excessive growth of extrauterine endometrial tissue, resulting in subsequent bleeding into the abdominal cavity and ovaries, and presenting with symptoms such as peritonitis and painful defaecation or urination. While levels of high-sensitivity C reactive protein (CRP),

a marker of inflammation, have been found to be significantly higher in women with endometriosis,<sup>13</sup> other studies have reported an association between elevated blood levels of high-sensitivity CRP and ischaemic stroke.<sup>14 15</sup> Inflammation resulting from endometriosis may therefore also be linked with an increased risk of ischaemic stroke. Our results suggest that endometriosis may increase the risk of cerebral infarction and TIA by triggering inflammation. The OR (95% CI) for comorbid endometriosis and ovarian cancer was 3.65 (2.16 to 6.19), which supports the conclusions of a previous study that found that endometriosis increases the risk of developing ovarian cancer.<sup>6</sup>

Anaemia was found to have a higher cumulative incidence (29.0% at 50 years of age). Anaemia is highly prevalent among women and may be diagnosed following pregnancy or heavy menstrual bleeding caused by uterine myoma. In the present study, the peak incidence for anaemia occurred at 36 years of age. Our results imply that relatively young, premenopausal women are more susceptible to anaemia than older, postmenopausal women. Our results also suggest a strong association between anaemia and gastric cancer. While anaemia can occur because of gastrectomy,<sup>16</sup> pernicious anaemia is associated with increased risk of gastric cancer.<sup>17–19</sup> The causal pathway, including a reverse effect, could not be determined because of the study's cross-sectional design. This study had a novel finding in that there was a significant negative association between anaemia and diabetes mellitus. Several studies have reported that body iron stores or elevated ferritin concentrations were associated with increased risk of type 2 diabetes mellitus,<sup>20 21</sup> potentially supporting our finding of the negative association between anaemia and diabetes mellitus.

The age at incidence peak of migraine headache was 44.8 years. Several studies reported that migraine was associated with oestrogen levels,<sup>7 8</sup> and the incidence significantly increased from menarche onwards.<sup>22 23</sup> Migraine also increased the risk of ischaemic stroke and cardiovascular disease in another study.<sup>9</sup> This study's findings of a significantly enhanced risk of TIA, cerebral infarction and angina pectoris in migraine sufferers appear to support this.

The cumulative incidence at 50 years of age of uterine myoma was 18.9%. Although uterine myoma is often asymptomatic, we diagnosed a number of participants with the condition after they underwent cancer screening or a prenatal test. Uterine myoma is associated with elevated body mass index<sup>24</sup> and body fat percentage,<sup>25</sup> suggesting that uterine myoma may be associated with obesity. Obesity is also associated with increased risk of colon cancer.<sup>26 27</sup> The OR of comorbid colorectal cancer was 2.31 (1.48 to 3.61) in this study, suggesting that obesity is a potential common risk factor for uterine myoma and colorectal cancer.

The estimated age at peak incidence of early-onset diseases, as well as other diseases in this study, revealed the nature of diseases in a woman's life course. The diseases

Table 3 MH common ORs (95% CI) for comorbidities

	Endometriosis			Anaemia			Migraine			Uterine myoma		
	MH OR	95% CI	p Value for the Breslow-Day test	MH OR	95% CI	p Value for the Breslow-Day test	MH OR	95% CI	p Value for the Breslow-Day test	MH OR	95% CI	p Value for the Breslow-Day test
Endometriosis												
Anaemia	2.31	(2.14 to 2.50)	0.225	2.31	(2.14 to 2.50)	0.225	1.96	(1.77 to 2.17)	0.652	4.47	(4.09 to 4.87)	0.449
Migraine headache	1.96	(1.77 to 2.17)	0.652	2.13	(2.01 to 2.27)	0.045	2.13	(2.01 to 2.27)	0.045	2.73	(2.57 to 2.90)	0.410
Uterine myoma	4.47	(4.09 to 4.87)	0.449	2.73	(2.57 to 2.90)	0.410	1.30	(1.20 to 1.42)	0.246	1.30	(1.20 to 1.42)	0.246
Cervical cancer	1.12	(0.74 to 1.69)	0.969	0.82	(0.64 to 1.06)	0.093	1.32	(0.98 to 1.78)	0.203	1.39	(1.04 to 1.85)	0.412
Thyroid disease	1.49	(1.27 to 1.75)	0.595	1.18	(1.07 to 1.31)	0.306	1.24	(1.09 to 1.41)	0.073	1.43	(1.27 to 1.61)	0.010
Breast cancer	1.34	(0.91 to 1.96)	0.272	0.76	(0.59 to 0.98)	0.212	0.82	(0.58 to 1.17)	0.061	1.54	(1.19 to 1.99)	0.119
Cholelithiasis	1.31	(1.04 to 1.65)	0.905	1.19	(1.04 to 1.36)	0.348	1.42	(1.20 to 1.69)	0.135	1.68	(1.44 to 1.95)	0.015
Subarachnoid haemorrhage	1.00	(0.31 to 3.22)	0.480	0.67	(0.32 to 1.38)	0.385	1.50	(0.70 to 3.21)	0.663	0.92	(0.41 to 2.05)	0.409
Transient ischaemic attack	1.91	(1.26 to 2.90)	0.748	1.44	(1.09 to 1.90)	0.899	3.06	(2.29 to 4.09)	0.384	1.38	(0.99 to 1.94)	0.529
Endometrial cancer	2.40	(1.14 to 5.04)	0.632	1.20	(0.68 to 2.09)	0.110	1.97	(1.05 to 3.70)	0.634	0.78	(0.35 to 1.74)	0.678
Diabetes mellitus	1.09	(0.79 to 1.51)	0.128	0.68	(0.56 to 0.84)	0.028	0.99	(0.77 to 1.28)	0.451	1.45	(1.19 to 1.77)	<0.001
Gastric cancer	0.87	(0.43 to 1.78)	0.946	3.69	(2.68 to 5.08)	0.879	1.06	(0.65 to 1.74)	0.252	1.04	(0.66 to 1.63)	0.539
Cerebral infarction	2.10	(1.15 to 3.85)	0.447	0.89	(0.56 to 1.42)	0.987	2.04	(1.26 to 3.30)	0.581	1.39	(0.85 to 2.25)	0.120
Ovarian cancer	3.65	(2.16 to 6.19)	0.208	0.94	(0.58 to 1.53)	0.995	1.51	(0.85 to 2.66)	0.291	1.60	(0.93 to 2.76)	0.539
Colorectal cancer	1.59	(0.80 to 3.16)	0.594	1.56	(1.02 to 2.37)	0.506	1.78	(1.06 to 2.97)	0.618	2.31	(1.48 to 3.61)	0.384
Angina pectoris	1.55	(1.03 to 2.32)	0.093	1.12	(0.86 to 1.45)	0.170	2.00	(1.49 to 2.67)	0.283	1.45	(1.09 to 1.91)	<0.001
Osteoporosis	1.89	(1.43 to 2.51)	0.532	1.49	(1.24 to 1.80)	0.010	2.11	(1.71 to 2.62)	0.622	1.54	(1.24 to 1.90)	0.441
Hypertension	1.26	(1.07 to 1.47)	0.003	0.98	(0.90 to 1.08)	0.035	1.69	(1.52 to 1.90)	0.455	1.50	(1.35 to 1.66)	<0.001
Hypercholesterolaemia	1.30	(1.15 to 1.47)	0.021	1.06	(0.98 to 1.14)	<0.001	1.35	(1.23 to 1.48)	0.237	1.36	(1.25 to 1.48)	<0.001

MH, Mantel-Haenszel.

included hypercholesterolaemia, hypertension and osteoporosis, which occur more frequently among post-menopausal women over 60 years of age. The cumulative incidences at 60 years of age for hypercholesterolaemia, hypertension and osteoporosis were 41.3%, 23.4% and 6.7%, respectively, and these diseases exhibited a marked increase in incidence after the perimenopausal period.

The peak incidence for breast cancer occurred at 50 years (figure 1B), indicating that Japanese women are more likely to develop the disease before menopause rather than after the perimenopausal period. Our results suggest that, unlike women in Western countries where the incidence of breast cancer increases with age even after menopause,<sup>28</sup> the incidence among women in Japan and other Asian settings exhibits a bell-shaped pattern with a peak at 45–50 years.<sup>29</sup> Our findings therefore support the current consensus that the incidence of breast cancer in Japan is higher before menopause than after.

This study has several limitations. In this study, we defined disease onset as a diagnosis by a medical doctor that was reported on the self-administered questionnaire. Participants could only report a diagnosis; asymptomatic or undiagnosed diseases were excluded. Use of diagnoses rather than self-reported prevalence may affect correlation in some diseases. Information on disease diagnosis was based on self-reporting, which may have led to a misclassification of diagnoses. However, nurses are likely to report such information more accurately than the general population because of their medical knowledge and clinical experience. In addition, our study population, which was composed entirely of nurses, was likely to exhibit different health behaviours and be exposed to different risk factors compared with the general Japanese population. Thus, our findings may not be generalisable to the national population, reducing this study's external validity. However, we have no reason to suspect that the general population of women would differ in terms of risk of comorbidity between early-onset and other diseases later in the life course. Additionally, data on disease histories were collected retrospectively, so only living participants were included in the survey. This may have led to an underestimation of disease incidence. Furthermore, we were unable to determine the causal relationship between comorbidities because of the cross-sectional design. Recall bias may have caused an overestimation of ORs since sick people tend to report more about disease history. However, since the participants were nurses, we think that recall bias was minimised since they have medical knowledge and are more likely to have answered correctly. A further analysis of the JNHS cohort using follow-up data is needed to determine the causal relationships between these comorbidities. Finally, women over the age of 60 years were under-represented relative to other age groups in the study.

## CONCLUSIONS

While there were significant associations between the four early-onset diseases (endometriosis, anaemia, migraine headache and uterine myoma), women with a history of early-onset diseases had a higher risk of other diseases later in the life course. Understanding the history of early-onset diseases in women may help reduce the subsequent risk of chronic diseases in later life. Further research based on follow-up studies is needed to clarify the cause–effect associations between these diseases.

### Author affiliations

<sup>1</sup>Unit of Community Health Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Gunma, Japan

<sup>2</sup>Department of Reproductive Technology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan

<sup>3</sup>Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan

<sup>4</sup>Public Health, Department of Social and Environmental Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

<sup>5</sup>Department of Environmental Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

<sup>6</sup>Department of Obstetrics and Gynecology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan

<sup>7</sup>Department of Comprehensive Reproductive Medicine, Tokyo Medical and Dental University, Tokyo, Japan

<sup>8</sup>Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan

**Acknowledgements** The authors appreciate the assistance of Mr Toshio Kobayashi and Dr Fumie Tokuda in data entry and management. They also appreciate the late Professor Toshiharu Fujita's contributions to the Japan Nurses' Health Study. This manuscript was checked by a native-English-speaking science editor.

**Contributors** KN analysed the data and drafted the report. KH designed and initiated the study. KN, KH, TY and KK contributed to the interpretation and discussion of the data and writing of the manuscript. KN, KH, TY, KK, HI, YK, AW, TK and HM approved the final draft to be published and agreed to account for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Funding** This study was supported partly by a Grant-in-Aid for Scientific Research (B: 22390128 to KH) from the Japan Society for the Promotion of Science.

**Competing interests** None.

**Patient consent** Obtained.

**Ethics approval** Gunma University and the National Institute of Public Health.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

## REFERENCES

1. Mishra GD, Anderson D, Schoenaker DA, *et al.* InterLACE: a new international collaboration for a life course approach to women's reproductive health and chronic disease events. *Maturitas* 2013;74:235–40.

2. Missmer SA, Hankinson SE, Spiegelman D, *et al.* Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. *Am J Epidemiol* 2004;160:784–96.
3. Yasui T, Matsui S, Tani A, *et al.* Androgen in postmenopausal women. *J Med Invest* 2012;59:12–27.
4. Lee JS, Hayashi K, Mishra G, *et al.* Independent association between age at natural menopause and hypercholesterolemia, hypertension, and diabetes mellitus: Japan nurses' health study. *J Atheroscler Thromb* 2013;20:161–9.
5. Fujita T, Hayashi K, Katanoda K, *et al.* Prevalence of diseases and statistical power of the Japan Nurses' Health Study. *Ind Health* 2007;45:687–94.
6. Aris A. Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie Region of Quebec, Canada. *J Ovarian Res* 2010;3:2.
7. MacGregor EA. Oestrogen and attacks of migraine with and without aura. *Lancet Neurol* 2004;3:354–61.
8. Brandes JL. The influence of estrogen on migraine: a systematic review. *JAMA* 2006;295:1824–30.
9. Bigal ME, Kurth T, Santanello N, *et al.* Migraine and cardiovascular disease: a population-based study. *Neurology* 2010;74:628–35.
10. Hayashi K, Mizunuma H, Fujita T, *et al.* Design of the Japan Nurses' Health Study: a prospective occupational cohort study of women's health in Japan. *Ind Health* 2007;45:679–86.
11. Hosmer DW, Lemeshow S, May S. *Applied survival analysis: regression modeling of time-to-event data*. 2nd edn. New Jersey: John Wiley & Sons, 2008:16–66.
12. Allison PD. *Survival analysis using SAS: a practical guide*. 2nd edn. Cary, NC: SAS Institute Inc., 2010:29–70.
13. Kinugasa S, Shinohara K, Wakatsuki A. Increased asymmetric dimethylarginine and enhanced inflammation are associated with impaired vascular reactivity in women with endometriosis. *Atherosclerosis* 2011;219:784–8.
14. Makita S, Nakamura M, Satoh K, *et al.* Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population. *Atherosclerosis* 2009;204:234–8.
15. Chei CL, Yamagishi K, Kitamura A, *et al.* C-reactive protein levels and risk of stroke and its subtype in Japanese: the Circulatory Risk in Communities Study (CIRCS). *Atherosclerosis* 2011;217:187–93.
16. Lim CH, Kim SW, Kim WC, *et al.* Anemia after gastrectomy for early gastric cancer: long-term follow-up observational study. *World J Gastroenterol* 2012;18:6114–19.
17. Mellemkjaer L, Gridley G, Møller H, *et al.* Pernicious anaemia and cancer risk in Denmark. *Br J Cancer* 1996;73:998–1000.
18. Ye W, Nyren O. Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia. *Gut* 2003;52:938–41.
19. Vannella L, Lahner E, Osborn J, *et al.* Systematic review: gastric cancer incidence in pernicious anaemia. *Aliment Pharmacol Ther* 2013;37:375–82.
20. Jiang R, Mason JE, Meigs JB, *et al.* Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. *JAMA* 2004;291:711–17.
21. Sun L, Franco OH, Hu FB, *et al.* Ferritin concentrations, metabolic syndrome, and type 2 diabetes in middle-aged and elderly Chinese. *J Clin Endocrinol Metab* 2008;93:4690–6.
22. Lipton RB, Stewart WF, Diamond S, *et al.* Prevalence and burden of migraine in the United States: data from the American Migraine Study II. *Headache* 2001;41:646–57.
23. Stewart WF, Lipton RB, Celentano DD, *et al.* Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. *JAMA* 1992;267:64–9.
24. Takeda T, Sakata M, Isobe A, *et al.* Relationship between metabolic syndrome and uterine leiomyomas: a case-control study. *Gynecol Obstet Invest* 2008;66:14–17.
25. Sato F, Nishi M, Kudo R, *et al.* Body fat distribution and uterine leiomyomas. *J Epidemiol* 1998;8:176–80.
26. Harriss DJ, Atkinson G, George K, *et al.*, C-CLEAR group. Lifestyle factors and colorectal cancer risk (1): systematic review and meta-analysis of associations with body mass index. *Colorectal Dis* 2009;11:547–63.
27. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. *Am J Clin Nutr* 2007;86:556–65.
28. Matsuno RK, Anderson WF, Yamamoto S, *et al.* Early- and late-onset breast cancer types among women in the United States and Japan. *Cancer Epidemiol Biomarkers Prev* 2007;16:1437–42.
29. Toi M, Ohashi Y, Seow A, *et al.* The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer. *Jpn J Clin Oncol* 2010;40 (Suppl 1):i13–18.